Abstract: Disclosed are a metal mesh touch screen and a method for manufacturing a metal mesh touch screen. The metal mesh touch screen includes the first functional electrode layer, a first adhesive layer, a second functional electrode layer and a second adhesive layer placed sequentially. The first functional electrode layer includes the first metal mesh wiring extending in a first direction and a metal material for preparing the first metal mesh wiring is a metal foil with a first rough surface and a second rough surface. The second functional electrode layer includes a second metal mesh wiring extending in a second direction and a metal material for preparing the second metal mesh wiring is the metal foil with the first rough surface and the second rough surface.

Abstract: A crystal form and salt form of a bromine domain protein inhibitor represented by formula (I), a preparation method therefor, and a use of the crystal form and salt form in the preparation of a drug for treating diseases mediated by BET protein.

Abstract: Disclosed herein are imidazotriazine and pyrrolopyrimidine derivatives or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a G12C inhibitors, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the imidazotriazine and pyrrolopyrimidine derivatives or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as G12C inhibitors.

Abstract: Disclosed are an electrothermal film structure, an electrothermal film heating device and a method for manufacturing an electrothermal film. The electrothermal film structure includes a supporting layer, a meshed conductive circuit layer and a transparent optical layer. The meshed conductive circuit layer provided on the supporting layer includes several micron-level conductive circuits distributed in a mesh, and the transparent optical layer is provided on the meshed conductive circuit layer.

Abstract: Disclosed are a metal mesh touch screen and a method for manufacturing a metal mesh touch screen. The metal mesh touch screen includes the first functional electrode layer, a first adhesive layer, a second functional electrode layer and a second adhesive layer placed sequentially. The first functional electrode layer includes the first metal mesh wiring extending in a first direction and a metal material for preparing the first metal mesh wiring is a metal foil with a first rough surface and a second rough surface. The second functional electrode layer includes a second metal mesh wiring extending in a second direction and a metal material for preparing the second metal mesh wiring is the metal foil with the first rough surface and the second rough surface.

Abstract: Disclosed herein are heterocyclic compounds that may be used as STING modulators, the process for synthesis and to the use of such compounds in treatment of various diseases including cancers.

Abstract: An imidazo [2,1-f] [1,2,4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof which are used as a TLR7 agonist in the treatment of cancer are provided. Pharmaceutical compositions comprising the imidazo [2,1-f] [1,2,4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof are also provided.

Abstract: Disclosed is an electrochromic material. The electrochromic material includes: a low eutectic solvent, and a color-changing material which includes a hydrogen bond donor material and a hydrogen bond acceptor material. The electrochromic material also includes an aerogel.

Abstract: The present invention relates to a novel polyurethane-based UV-curable composition, comprising a low-crystallinity polyurethane polymer, a multifunctional thiol compound, a multifunctional epoxy resin compound, a photobase generator, and an optional photosensitizer. Adhesive films, adhesive tapes, and bonded members with excellent initial bonding performance, die cutting performance, overlap strength and drop-resistance performance may be obtained by using the polyurethane-based UV-curable composition provided by the present invention.

Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.

Abstract: Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as an A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an A2A receptor antagonist.

Abstract: Disclosed are an imidazo[2,1-f][1,2,4]triazin-4-amine derivative used as a TLR8 agonist or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing same. Further disclosed is a method for treating cancers using the imidazo[2,1-f][1,2,4]triazin-4-amine derivative or the stereoisomer thereof or the pharmaceutically acceptable salt thereof as a TLR8 agonist.

Abstract: A test device and method for top-of-the-line corrosion (TLC) of a high-temperature high-pressure wet gas pipeline. The device mainly includes: a metal top cap, a metal reaction cylinder, a first thermometer, a second thermometer, a plastic transparent measuring cylinder, a condensed water collection tube, an atomic spectrometer, a third thermometer, a rubber seal cover, a condensate droplet, a threaded hole, a condensation chamber, a pipeline sample, a temperature measuring hole, and a 30-degree tilt angle. The device and method can effectively simulate TLC of a wet gas pipeline under a high-temperature high-pressure environment. The device and method can test the high-temperature high-pressure TLC of the wet gas pipeline under different temperature differences (between a surface temperature of the pipeline and a gas temperature) and various corrosion media.

Abstract: Disclosed herein is an imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a TLR7 agonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as TLR7 agonist.

Abstract: Disclosed herein is a physically stable solid dispersion comprising Compound 1, i.e., the B-RAF kinase dimer inhibitor 1-((1S, 1aS, 6bS)-5-((7-oxo-5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa [b]benzofuran-1 yl)-3-(2, 4, 5-trifluorophenyl) urea and a specific stabilizing polymer, the method for preparing the same, and the uses of the solid dispersion. Also disclosed herein is the crystalline form of Compound 1.

Abstract: A mobile device includes a sensing unit configured to determine whether the stylus pen is separated from the mobile device; a communication unit configured to receive a control signal including a first control signal and a second control signal from the stylus pen separated from the mobile device; and a controller configured to operate in a first control mode for performing an operation of an application being executed on the mobile device. The controller performs a first operation of the application in response to the first control signal, and performs a second operation of the application in response to the second control signal.

Abstract: Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.

Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.

Abstract: Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as an A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an A2A receptor antagonist.

Abstract: Disclosed herein are 5 or 8-substituted imidazo [1, 5-a] pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo [1, 5-a] pyridines, processes for the preparation thereof and the use thereof in therapy. Disclosed herein are certain 5 or 8-substituted imidazo [1, 5-a] pyridines that can be useful for inhibiting indoleamine 2, 3-dioxygenase and/or tryptophane 2, 3-dioxygenase and for treating diseases or disorders mediated thereby.